Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Ablation with Camrelizumab and Chemotherapy for Pancreatic Cancer with Liver Metastasis
NCT06307080Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Safety and efficacy assessment at 1 year. Started Oct 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06307080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307080.